Glycine amides as PPARalpha agonists.
The design, synthesis and pharmacological properties of a novel class of PPARalpha agonists is described. Compound 2 is a novel, potent and specific glycine amide with oral bioavailability in rodents. The compound is active in vivo and alters plasma lipids in hAPO-A1 transgenic mice after oral administration.
Urbahns
Klaus
K
Department of Medicinal Chemistry, Bayer Healthcare, Bayer-Schering Pharma, D-42096 Wuppertal, Germany. Klaus.Urbahns@astrazeneca.com
Woltering
Michael
M
Nikolic
Susanne
S
Pernerstorfer
Josef
J
Bischoff
Hilmar
H
Dittrich-Wengenroth
Elke
E
Lustig
Klemens
K
D000818:Animals; D001682:Biological Availability; D005998:Glycine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology; D051379:Mice; D008822:Mice, Transgenic; D047493:PPAR alpha / Q000819:agonists*; D013329:Structure-Activity Relationship
D047493:PPAR alpha; C018556:glycine amide; D005998:Glycine